C4 Therapeutics Inc (NASDAQ:CCCC) price on Thursday, February 27, fall -1.89% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.60.
A look at the stock’s price movement, the close in the last trading session was $2.65. Turning to its 52-week performance, $11.88 and $2.62 were the 52-week high and 52-week low respectively. Overall, CCCC moved -28.37% over the past month.
C4 Therapeutics Inc’s market cap currently stands at around $183.53 million, with investors looking forward to this quarter’s earnings report slated for in March.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CCCC is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 1 recommend CCCC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CCCC’s current price about -18.65% and -27.36% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 24.79, while 7-day volatility ratio is 7.43% and 6.88% in the 30-day chart. Further, C4 Therapeutics Inc (CCCC) has a beta value of 3.00, and an average true range (ATR) of 0.23. Analysts have given the company’s stock an average 52-week price target of $16, forecast between a low of $12 and high of $20. Looking at the price targets, the low is -361.54% off current price level while to achieve the yearly target high, price needs to move -669.23%. Nonetheless, investors will most likely welcome a -515.38% jump to $16 which is the analysts’ median price.
If we refocus on C4 Therapeutics Inc (NASDAQ:CCCC), historical trading data shows that trading volumes averaged 1.88 million over the past 3 months. The company’s latest data on shares outstanding shows there are 70.56 million shares.
The 20.14% of C4 Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 83.65% of the company’s shares. Current price change has pushed the stock -27.78% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CCCC stock continues to rise going into the next quarter.
